The overall goal of this project is to elucidate the pathogenic processes underlying reactive (secondary) amyloidosis. This disease develops as a complication of chronic inflammation and is characterized by extracellular deposits of amyloid A (AA) protein, a peptide proteolytically derived from the acute phase protein, serum amyloid A (SAA). Although the pathogenesis of reactive amyloidosis remains largely undefined, macrophages have long been implicated to play a role possibly through altered metabolic processing of SAA. Macrophages cultured in the presence of recombinant SAA2 exhibit amyloid deposition and thus represent a manipulatable system for studying pathogenesis at the cellular level. This system will be employed to test the hypothesis that the amyloidogenic pathway of SAA involves trafficking through macrophages along a course similar to that followed by transferrin, i.e., concentration in coated vesicles, delivery to acidic sorting endosomes, and subsequent trafficking through recycling compartments with translocation to the cell surface, the site of amyloid fibril deposition. Experiments will be carried out to: (a) characterize the binding, uptake, accumulation in/on cells, release into the medium, and degradation of highly amyloidogenic SAA2 under optimal amyloid-forming conditions, (b) simultaneously track SAA2 and transferrin through macrophages using fluorescent immunocytochemistry, and (c) localize SAA2 at the ultrastructural level using immunogold electron microscopy. The same studies will then be performed using non-amyloidogenic CE/J SAA proteins. By comparing the fates of these proteins, it will be possible to identify metabolic events which distinguish the amyloidogenic pathway from non-amyloidogenic (degradative) pathway. The metabolic step at which amyloid-enhancing factor (AEF) exerts its influence will also be determined. An understanding of the cellular pathway leading to amyloid formation should greatly facilitate the development of strategies to prevent or arrest amyloid fibril formation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK049730-06
Application #
6177194
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Mckeon, Catherine T
Project Start
1995-06-01
Project End
2003-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
6
Fiscal Year
2000
Total Cost
$203,409
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Genetics
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Magy, Nadine; Benson, Merrill D; Liepnieks, Juris J et al. (2007) Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. Amyloid 14:51-63
Ray, Donna; Wu, Ailing; Wilkinson, J Erby et al. (2006) Aging in heterozygous Dnmt1-deficient mice: effects on survival, the DNA methylation genes, and the development of amyloidosis. J Gerontol A Biol Sci Med Sci 61:115-24
Magy, Nadine; Liepnieks, Juris J; Benson, Merrill D et al. (2003) Amyloid-enhancing factor mediates amyloid formation on fibroblasts via a nidus/template mechanism. Arthritis Rheum 48:1430-7
Yamada, Toshiyuki; Okuda, Yasuaki; Takasugi, Kiyoshi et al. (2003) An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid 10:7-11
Kluve-Beckerman, Barbara; Manaloor, John J; Liepnieks, Juris J (2002) A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 46:1905-13
Kluve-Beckerman, B; Manaloor, J; Liepnieks, J J (2001) Binding, trafficking and accumulation of serum amyloid A in peritoneal macrophages. Scand J Immunol 53:393-400
Kluve-Beckerman, B; Yamada, T; Hardwick, J et al. (1997) Differential plasma clearance of murine acute-phase serum amyloid A proteins SAA1 and SAA2. Biochem J 322 ( Pt 2):663-9